Rani Therapeutics Holdings, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $99.8M
- Price
- $0.8882
- % Change (Daily % change from the live per-ticker quote feed.)
- +4.38%
- Volume
- 364.2K
About
Rani Therapeutics Holdings, Inc. functions as a clinical-stage biopharmaceutical enterprise focused on revolutionizing the delivery of biologic therapies through oral administration. Its flagship innovation, the RaniPill capsule, aims to supplant conventional subcutaneous or intravenous injections of biologics with a more convenient oral dosing method. The company maintains a comprehensive portfolio of investigational treatments. Among these is RT-101, an octreotide, which has progressed beyond Phase I clinical trials for the management of neuroendocrine tumors and acromegaly. Another promising candidate is RT-105, an anti-TNF-alpha antibody designed to address psoriatic arthritis. Additionally, RT-102, a parathyroid hormone for osteoporosis, is currently advancing through preclinical studies. Other therapies under development include RT-109, a human growth hormone for treating growth hormone deficiency; RT-110, a parathyroid hormone aimed at hypoparathyroidism; and RT-106, a basal insulin formulated for type 2 diabetes. Established in 2012, the company's corporate base is located in San Jose, California.
Quick stats
Shares outstanding112.4M
Computed float76.6M
Float / shares68.1%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001856725
AI Summary
AI-generated1/14
majorbullishearnings
Rani Therapeutics Reports Second Quarter 2026 Financial Results; Provides Corporate Update
Rani Therapeutics reported Q2 contract revenue of $1.7 million, driven by its collaboration with Chugai, and narrowed its net loss to $8.4 million compared to the prior year.
The company announced positive initial Phase 1a data for RT-114, achieving bioavailability greater than 150% relative to subcutaneous dosing, and expanded its obesity pipeline through a new R&D collaboration with PegBio.
With $53.4 million in cash following a $20 million registered direct offering, Rani expects to fund operations into at least 2027.
Red flags
- General and administrative expenses increased 10% year-over-year
- Company remains unprofitable with Q2 net loss of $8.4 million